VERAXA Biotech AG has appointed Carl von Halem as its interim Chief Financial Officer, succeeding Torsten Bürgermeister. Von Halem has been instrumental in taking VERAXA public and brings extensive experience in finance and life sciences. The company is finalizing discussions with a permanent CFO to support its growth and will update the market in due course. This leadership change aims to support VERAXA's next phase of expansion in developing novel cancer therapies.
Kaspi is currently trading at a low forward P/E of 7.6 despite maintaining high profitability with net margins and return on equity above 40%. The company's expansion into Turkey is currently reducing earnings but is expected to drive significant rev...
The BIP-110 Bitcoin fork has stalled after miners produced only two blocks in eight hours, while Bitcoin's main chain advanced by 48 blocks. This fork inherited Bitcoin's mining difficulty despite having very limited mining power, causing extremely s...
MARA Holdings secured $600 million in Bitcoin-backed loans by pledging 18,750 BTC, over half its Bitcoin treasury, to finance a new power-generation site aimed at supporting AI and high-performance computing. The loans, part of a $750 million facilit...
XRP is trading near $1.04, showing early signs of a possible macro bottom but still facing key support tests at $1.00. Analyst EGRAG Crypto highlights $1.00 as a critical support level that XRP must defend to avoid dropping to $0.70-$0.80, with $1.35...
Travelzoo has announced new exclusive travel deals for its Canadian Club Members, featuring discounted packages to destinations like Portugal, the Maldives, British Columbia, and Antigua. Offers include a $799 Portugal coastal getaway with flights, a...
